Table 2.
Association of loss of Y-chromosome (LOY) with male breast cancer (BC) clinicopathological characteristics (n = 722).
| Patient and Tumor Characteristics | XY Status | p-Value | |
|---|---|---|---|
| XY (Range/%) | X_ (Range/%) | ||
| Age at diagnosis | 0.311 | ||
| Median (years) | 67.0 (25–95) | 64.5 (34–98) | |
| Tumor size (missing; n = 362) | 0.093 | ||
| Median (mm) | 20.0 (1–110) | 21.0 (0–90) | |
| Grade (missing; n = 26) | 0.056 | ||
| Low | 161 (26.5) | 13 (14.7) | |
| Intermediate | 306 (50.3) | 53 (60.2) | |
| High | 141 (23.2) | 22 (25.0) | |
| Precursor lesion (missing; n = 24) | 0.605 | ||
| None | 317 (52.0) | 48 (54.5) | |
| DCIS | 287 (47.0) | 40 (45.5) | |
| Other | 6 (1.0) | 0 (0.0) | |
| TIL density (missing; n = 28) | 0.268 | ||
| Minimal-Mild | 515 (85.0) | 13 (54.2) | |
| Moderate-Severe | 91 (15.0) | 11 (45.8) | |
| ER status (missing; n = 41) | 0.017 | ||
| ER+ | 561 (94.4) | 76 (87.4) | |
| ER− | 33 (5.6) | 11 (12.6) | |
| PR status (missing; n = 34) | 0.01 | ||
| PR+ | 448 (74.4) | 53 (61.6) | |
| PR− | 154 (24.6) | 33 (38.4) | |
| AR status (missing; n = 32) | 0.327 | ||
| AR+ | 428 (67.9) | 67 (72.8) | |
| AR− | 174 (27.6) | 21 (22.8) | |
| HER2 status (missing; n = 17) | 0.542 | ||
| HER2+ | 29 (4.7) | 3 (3.3) | |
| HER2− | 585 (95.3) | 88 (96.7) | |
| IHC subtype (undetermined; n = 60) | 0.242 | ||
| ER+/-PR+/-HER2− | 525 (90.7) | 72 (86.7) | |
| ER+PR+/-HER2+ | 27 (4.6) | 3 (3.6) | |
| ER-PR-HER2+ | 1 (0.2) | 0 (0.0) | |
| ER-PR-HER2− | 26 (4.5) | 8 (9.6) | |
| Distant metastasis (missing; n = 451) | 0.157 | ||
| Yes | 54 (22.6) | 3 (10.8) | |
| No | 189 (79.4) | 25 (89.2) | |
| Survival (missing; n = 5) | 0.469 | ||
| Alive | 240 (38.4) | 30 (33.0) | |
| Dead | 386 (61.6) | 61 (67.0) | |